Insights in Medical Science

Editorial Panel

Mirko Diksic
Professor Emeritus, Department of Neurology and Neurosurgery, McGill University, Montreal.
BiographyBiochemical processes in the central nervous system (CNS) are hard to investigate, due to the unavailability of samples from the CNS in the in vivo investigations. There are only a few direct methods that enable us to determine the biochemical processes in the human brain during its life span. Today, basic studies in the field of radiochemistry have been found in the investigation of the biochemical processes in the CNS. Mirko Diksic is a scientist who has successfully used his abundant experience in basic sciences and applied that knowledge to neurobiological and neuropharmacological research. After joining the Montreal Neurological Institute in 1979 Mirko Diksic, along with a research group, devised and set up the first medical cyclotron facility in Canada designed exclusively for medical research. The cyclotron was opened in 1981, and was used very successfully for research until 1991, when it was replaced with a new and improved machine still used today. He made a substantial contribution to the development of the methods for the synthesis of radioactive labeled compounds used medical research. At the same time, Mirko Diksic established a radiochemical laboratory to prepare biologically active molecules marked with the short living 18F md 11C radioisotopes. These labeled molecules have been used in investigations of processes in the human CNS in vivo using PET. Mirko Diksic made a significant contribution to oncological brain research. Soon after the installation of the cyclotron, one of the first radioactively labeled radiopharmaceuticals was a drug named Carmustine (1,3 di-chloroethylen nitrosourea, BCNU), that is often used in the treatment of brain tumors. Mirko Diksic was the first person to demonstrate that the effects of BCNU depend on its routes of administration. Using PET studies, it was determined that 11C-BCNU following intra-arterial administration accumulated in brain tumors 50% more than after intravenous administration. A great deal of Mirko Diksic's scientific work is connected to studies in the control of the synthesis rate of the neurotransmitter (serotonin) in the CNS. It is assumed that alterations of the serotonergic system in the brain are related to psychiatric disorders such as depression, schizophrenia, eating disorders and substance abuse disorders (alcoholism). At the end of the 20th Century Mirko Diksic, together with associates from both Japan and Croatia, investigated the effects of psychotropic drugs that produce their effects via the serotonergic system, on the rate of serotonin synthesis. It has been shown that the anorectic drug fenfluramine and the antidepressant drug fluoxetine (better known as Prozac) increase the rate of serotonin synthesis in nerve terminal regions (cortices, striatum, hippocampus), while they simultaneously decrease the rate of serotonin synthesis in the regions of the serotonergic cell bodies. Furthermore, the effect seems to be different after acute and chronic administration. The obtained data indicated that alterations of serotonergic receptors activity may be one of the factors involved in the regulation of serotonin synthesis. Mirko Diksic is one of the first scientists to determine the rate of serotonin synthesis in the human brain in vivo, using 11C-alpha-methyltryptophan synthesized in his own laboratory. The most significant contribution of this study was the finding that the rate of serotonin synthesis in healthy male and female brains is differently affected by mild stress produced by lowering body tryptophan.
Pierre A. Guertin
Full Professor, Department of Psychiatry and Neurosciences, U. Laval President and Chief Executive Officer, Nordic Life Science Pipeline Inc.
BiographyDr. Guertin has 26 years of experience in spinal cord research and 14 years of experience in science leadership. He was President and CEO of NeuroSpina Therapeutics between 2005 and 2008 and Chief Scientific Officer of Eurymedon HealthCare during the same period. Over the years, he has obtained several million dollars in financing from not-for-profit organizations and foundations to conduct fundamental research in rodents, drug development and clinical studies. He has developed a cutting-edge expertise in neurological trauma, metabolic problems, sexual dysfunction, muscular and bone degradation and other accelerated aging-related problems and dysfunctions. He has received a B.Sc. degree (1989 - Kinesiology) from University of Montr�al, a M.Sc. degree (1992 - Neurokinetic) from University of Qu�bec in Montr�al and a Ph.D. degree (1996 - Neurophysiology) from University of Manitoba. He then pursued his training as a postdoctoral fellow between 1996 and 2000 in Denmark (Panum Institute, Copenhagen), England (University of Oxford), France (University of Aix-en-Provence II), and Canada (Universit� de Montr�al). In addition to his current position as President and CEO of Nordic Life Science Pipeline, he holds also positions (tenure-track) as Full Professor in the Department of Psychiatry & Neurosciences at Universit� Laval (2001 - present) and as of Director/Principal Investigator of the Spinal Cord Injury and Functional Recovery Laboratory (2002 - present) based in Qu�bec City (Laval University Medical Center � CHUQ/CHUL). As a leading scientist, he has published more than 100 articles and communications since 1990. He acts also as associate editor and external referee for several peer-reviewed journals as well as reviewer (external and internal) for Canadian and U.S. granting agencies (CIHR, NSERC, FRSQ, U.S. Congress).
Syed A. A. Rizvi
Professor Department of Pharmaceutical Sciences College of Pharmacy Health Professions Division Nova Southeastern University USA
BiographyDr. Rizvi pursued an M.S and Ph.D combined degree program at the Center for Biotechnology and Drug Design, Department of Chemistry, Georgia State University (GSU), Atlanta, GA. While working at GSU, Dr. Rizvi was trained in the areas of Analytical Chemistry, Separation Sciences, Bioanalysis, Surfactant Chemistry, Chiral Separations of the Drugs, Trace Level Analysis (Forensic Chemistry) of Drugs in human body fluids (led to a US and International patent). Right after finishing M.S and Ph.D at the GSU, Dr. Rizvi pursued another Ph.D (under Prof. Martin J. D�Souza) at the College of Pharmacy and Health Sciences, Department of the Pharmaceutical Sciences, Mercer University (MU), Atlanta, GA in collaboration with Dr. Scott L Childs (founder and chief Scientific officer, Renovo Research, LLC). At Mercer, Dr. Rizvi was trained in the areas of Solid Dosage Formulations (direct compressed tablets), Controlled Release Formulations, Nanoparticulate System for Non-Invasive real time In Vivo Imaging, Cell-Lipid interaction Studies. At Renovo, Dr. Rizvi was trained in the area of Solid State Chemistry of the Drugs, e.g., Polymorphism and Cocrystallization . Dr. Rizvi also pursued postdoctoral research in the laboratory of Dr. Fredric M. Menger (Charles Howard Candler Professor) at the Sanford S. Atwood Chemistry Center, Emory University, where he polished his skills in Organic Synthesis, Soft Material Chemistry, Surface and Interfacial Sciences, Gene Transfection Studies using Gemini Surfactants, State of the art, Langmuir-Adam Balance Studies. Moreover, Dr. Rizvi conducted research as a visiting scientist in the area of pharmaceutical ionic liquids, in the laboratory of Dr. Robin D. Rogers (Robert Ramsay Chair of Chemistry, Distinguished Research Professor and Director, Center for Green Manufacturing) at the Department of Chemistry, The University of Alabama. At the University of Alabama, Dr. Rizvi, Synthesized new salts and ionic liquids of the pharmaceutical compounds with improved solubility and permeability and with prophylactic counter-�ions for reduction in drug induced toxicity. Characterized the newly synthesized ionic liquid with NMR, IR, TGA, DSC, X-ray and Karl Fischer titration and In vivo studies (transdermal formulations) of various ionic liquids. Recently, Dr. Rizvi finished course of studies leading to Master of Business Administration (MBA) degree with specialization in Pharmaceutical Marketing and Management from Aspen University and a certificate in Executive Leadership from Johnson Graduate School of Management, eCornell Professional Development Programs, Cornell University. Dr. Rizvi has Published 103 peer reviewed articles that including, 51 journal papers, 48 oral and poster presentation abstracts, 2 book chapters, 1 text book, and 1 US patent (US8168440). Dr. Rizvi's publications include two most highly rated articles, two cover articles and one figure from Dr. Rizvi�s paper was included in the textbook �Quantitative Chemical Analysis� by Daniel C. Harris (7th Edition, p 616, W. H. Freeman, 2006, ISBN-10: 0716770415). Dr. Rizvi also presents his work through posters and oral presentations in national and international conferences. Dr. Rizvi serves as editor-in-chief, associate editor, executive editor and editorial board member for 35 different journals (various capacities) and review manuscripts and books for 76 well known scientific publications (journals and books). Dr. Rizvi enjoys teaching and engaging students in thought process and practice Martial Arts.
Sandeep K. Vashist
Senior Scientist in in vitro diagnostics (IVD) and point-of-care testing (POCT), Royal Melbourne Institute of Technology, Australia
Alma Rus Martinez
Department of Cellular Biology, University of Granada, SPAIN
Solhe F. Alshahateet
Associate Professor, Department of Chemistry, Faculty of Science, Mu'tah University, Jordan
Claudio Nastruzzi
Department of Life Sciences and Biotechnology, University of Ferrara, Italy
BiographyClaudio Nastruzzi was born in Ferrara on March 29, 1958. 1983 - Degree in Pharmaceutical Chemistry at the University of Ferrara, Department of Pharmaceutical Science. 1983-1984 - Fellow in the Department of Pharmaceutical Science of University of Ferrara, working on natural compound synthesis (prostaglandins and leukotriens) and characterization of isosazolic and isosazolinic nuclei reactivity. 1988 - Ph.D. in Pharmaceutical Science, with a dissertation on the syntesis, antitumor and antimetastatic activity of aromatic polyamidines. 1988-1990 - Post-doctoral position at the Institute for Polymers of the Eidgenissische Technische Hochschule, (Swiss Federal Institute of Technology) (ETH), Zrich in the group of Prof. P.L. Luisi. 1990-1991 - Post-doctoral position at the Department of Pharmaceutical Sciences of the University of Ferrara, having as main topic the production and characterization of liposomes especially designed for retinoids delivery. Biophysical studies and activity on in vitro cultured cell lines. 1991-1998 - Researcher position at the Department of Pharmaceutical Sciences of the University of Ferrara, investigating the production of microspheres, liposomes and microemulsions for the controlled delivery of biological response modifiers. 1998-2009 - Associated Professor at the Dipartimento di Chimica e Tecnologia del Farmaco, of the University of Perugia, Perugia, Italy. 2009-2012 - Associated Professor at the Dipartimento di Scienze Farmaceutiche, of the University of Ferrara, Ferrara, Italy. 2012-Present - Associated Professor at the Dipartimento di Scienze della Vita e Biotecnologie, of the University of Ferrara, Ferrara, Italy.
Nan Mei
Division of Genetic and Molecular Toxicology National Center for Toxicological Research U.S. Food and Drug Administration U.S.A
BiographyDr. Nan Mei is a Research Biologist in the Division of Genetic and Molecular Toxicology at the FDAs National Center for Toxicological Research (NCTR). After graduating from Hebei Medical University (China) in 1984, he started his scientific career in clinical cancer research and diagnosis as a physician in a university hospital. In 1997 he received his Ph.D. degree in Applied Health Sciences from the University of Occupational and Environmental Health, Japan. He then extended his training on assessing DNA damage as a postdoctoral and Research Fellow at the Cross Cancer Institute in Canada and at the Institute of Industrial Ecological Sciences in Japan, respectively. In November of 2002, Dr. Mei joined FDA/NCTR. Currently his research focuses on genetic toxicology and toxicogenomics. He utilizes the in vivo transgenic mutation assays and in vitro genotoxicity assays to evaluate a number of FDA-relevant chemicals and model carcinogens for their mutagenicity and to determine the mechanisms of chemical-induced genetic toxicity. His interests include the evaluation of the mutagenic effects of direct mutagens, botanicals, herbal dietary supplements, industrial chemicals, nanomaterials, tobacco products, cosmetic ingredients, and other retail products. Dr. Mei incorporates toxicogenomic approaches to develop potential biomarkers, create gene signatures, and elucidate molecular mechanisms. Dr. Mei has published >80 peer-reviewed research articles in prestigious journals and 11 book chapters. He is a member of the Society of Toxicology (SOT), the Environmental Mutagenesis and Genomics Society (EMGS), and the Genetic Toxicology Association (GTA).
Shabina Rehman
Department of Basic pharmaceutical Sciences West Virginia University School of Pharmacy Morgantown, USA
Anil S Modak
Medical products research and development Cambridge Isotope Laboratories Inc., 3 Highwood drive,Tewksbury, USA
Hisham R. Ibrahim
Professor Department of Biochemistry and Biotechnology, The Graduate School of Agricultural Sciences, Kagoshima University, Japan
Jana Mahadevan
Staff Scientist at Washington University School of Medicine Demographic, United States